FDA approves Fusion's sealant for neurosurgical use:
This article was originally published in Clinica
Executive Summary
Fusion Medical Technologies' will expand the use of its Proceed haemostatic sealant into neurosurgical and cranial applications. The product can now be targeted for use in around 240,000 neurosurgical/cranial procedures that are performed every year worldwide, says Fusion, of Fremont, California. It will be sold in the spinal and cranial markets by Sulzer Spine-Tech, which estimates that the annual worldwide market for the device in cranial applications is worth $15-20 million.
You may also be interested in...
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.
Probiotics And Cold Remedies Boost Recordati In 2023
Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.
Falling Sales Force New Priorities At Roche
The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.